In the late 1980s, while working as a banking analyst, I actually got up-close and personal with Carl Reichardt, who was CEO of Wells Fargo & Co. (NYSE: WFC) at the time.
And something he shared with me in his spacious San Francisco office has stayed with me ever since.
I asked Reichardt if Wells Fargo’s focus on home and middle-market loans might be considered boring when other banks were chasing more exotic investments with higher yields.
He looked me straight in the eyes and said, “If plain vanilla means making a lot of money, then color me plain vanilla.”
I bring this up because I’ve spotted a dental-technology firm that investors might at first consider ho-hum – but that’s soared 80% in the past year. That’s five times the gains of the S&P 500 during the same period.
Yes, investing in a dental company may sound dull – or maybe even painful – but this is actually a profit-producing tech superstar.
After a painfully quiet 2016, initial public offerings both current and future have rebounded with gusto through the first four months of 2017.
So far, 45 IPOs have priced this year – nearly three times as many as at this point last year, according to Renaissance Capital, which tracks initial offerings.
The rebound started with Snap Inc. (NYSE: SNAP)’s $3.4 billion IPO in March – and has been followed up by offerings from the likes of Cloudera Inc. (NYSE: CLDR), Okta Inc. (Nasdaq: OKTA), and Mulesoft Inc. (NYSE: MULE).
It was a spring day back in 1992. My buddy Tim had clambered to the top of an under-construction townhouse – sent by his boss to start sheeting the roof trusses on the four-story structure.
Tim (a pseudonym, since this is a true story) – a fellow muscle-car nut and a guy my best friend, Harry, and I had known since high school – was working as a carpenter. Indeed, he was one of the best you’d find.
Tim’s life was about to change – forever.
Before Tim climbed up into the rafters, his boss – the site foreman – had said that all the trusses had been nailed down a day or two before. Once up on top, trying to reposition himself, my buddy temporarily straddled two of the squat lumber triangles.
Those trusses suddenly started to spread.
They weren’t nailed down.
Tim grabbed at the closest truss – but lost his handhold when it rolled under his weight.
And he fell.
What actually happened was that he plunged through the rectangular floor openings at each story – openings that would hold the staircases needed to climb from the ground-floor doorway all the way to the top.
My friend remembers getting both his arms, at chest level, onto the edge of one of those openings on the third or second floor – a move that slowed his fall and probably saved his life.
But he still slammed into the ground with a force that, even today, makes my skin crawl to think about.
And he was a denizen of an entirely new world.
A world of doctors, operations, physical therapy…
I’m sharing this story here today for a reason.
A bunch of reasons, actually.
I’m going to tell you about a biotech stock that I like a lot that focuses on the very real problem of chronic pain. It’s a company that’s looking at this malady in new ways.
But I also want to show you how to find still more stocks like this one – companies that are establishing whole new paradigms in biotechnology, life sciences and pharmaceuticals. It’s a brand-new business – one that I’m jazzed to tell you all about.
It’s been shown time and time again that the first entities to establish a strong base of business in a young and fast-growing market can reap major benefits. Being first in on an opportunity in a growth industry usually means huge profits… and leaves your competitors perennially trying to play catch-up.
After Snap Inc. (NYSE: SNAP) released its first quarterly report as a public company, investors did not like what the saw. And they punished it – sending shares down 20%.
Michael doesn’t like the stock either – yet – but he does see a “silver lining” in that report. It’s something Snap-curious investors should be keeping an eye on. He revealed what he saw last night during an appearance on CNBC World. Check it out below…
The days when marijuana “edibles” were limited to a bunch of teens passing around a pan of homemade pot-laced brownies are long over.
The legal marijuana industry now grosses more than $5.4billion a year through the sale of cannabis-infused food and drinks – for people who want to avoid the harmful effects of smoking, but still want the drug’s potent effects. And as marijuana continues its march to legalization, that number will keep climbing.
That means “edibles” re one of the most lucrative legal marijuana opportunities on the market. As I told you just yesterday, according to the “inside info” I picked up from New Frontier Data, use of edibles and concentrates (that is, vaping) each nearly tripled in the last year, eating into the smokable form’s market dominance. They now compose 33% of the total market – and that number is climbing.
Now I want to show you one of my favorite speculative plays in this booming pot-stock niche. I recommended it last September in my Nova X-Report “weed investors’ bible” – The Roadmap to Marijuana Millions – and some of the peak gains we’ve seen there have been extraordinary.
In fact, I can’t think of a better way to show everyone the massive profit potential in legal weed investing.
One of my team members was at a medical marijuana insiders meeting at his home base in Maryland last week – and he got ahold of some outstanding information that’s not yet been shared with the larger public.
On Tuesday, we talked about a “Trump-proof” way to play China’s exploding social media and e-commerce markets.
I told you I would follow up soon with another tech-based “frontier” investment.
Today I’m keeping that promise.
With 1.3 billion residents, India is the globe’s second-most-populous nation. And it could surpass China in as little as five years.
India logged GDP growth of 7% in last year’s fourth quarter. That beat forecasts by 10%. Even if that were to slow by as much as 20%, India’s economy would still be expanding twice as fast as that of the United States.
In just the past decade, India’s $2.2 trillion economy has leapt past Italy, Brazil, Canada, South Korea, and Russia. That means it’s now the globe’s seventh-largest economy – and it could move up to fifth place by 2020.
That kind of growth makes India one of the most enticing frontier investing markets today. And we know high tech is set to play a central role in this massive opportunity.
While India has a rich history of economic and business growth, it’s equally well known for its “threat landscape.” Corruption, crime, political instability, and terrorism all scare away many investors.
That’s why I’ve searched high and low for a way to get in on India’s ferocious tech growth – a way to get on the “sadak to wealth” – without exposing ourselves to those sorts of risks.
But that still offers hope of quick triple-digit gains…
This highly populated country is growing twice as fast as the United States. Plus, this global economic powerhouse keeps beating forecasts.
Yet over the past two years, one analyst after another – except for yours truly – has sounded the alarm and told investors to stay far, far away.
I’m starting to think that Wall Street just doesn’t understand China – or Frontier Investing… at all.
Are we even looking at the same data?
China just saw first-quarter GDP growth rate of 6.9%
That was its fastest pace of economic expansion since the third quarter of 2015… it was more than 5% above the nation’s own forecasts… and it came at a time when President Donald Trump was still blaming the world’s most populous country for unfair trade programs.